{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:33Z","timestamp":1787016933273,"version":"build-2736575974"},"reference-count":27,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University Hospitals Coventry and Warwickshire Charity","award":["G0227"],"award-info":[{"award-number":["G0227"]}]},{"name":"University Hospitals Coventry and Warwickshire Charity","award":["G0456"],"award-info":[{"award-number":["G0456"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Significant advances in systemic therapy have improved survival for patients with advanced-stage non-small cell lung cancer (NSCLC). However, the present treatment strategies and dose-fractionation for high-dose palliative radiotherapy (RT) are based on trials from the 1990s, when RT planning was simple with less precise delivery. Contemporary lung RT uses 4D-CT, volumetric modulated arc radiotherapy, aided by online verification using cone beam CT, which enables greater accuracy and better target volume coverage, while reducing doses to normal organs at risk. The Shortened High-dose Palliative Radiotherapy for Lung Cancer study aims to evaluate the safety and feasibility of reducing the number of RT fractions and RT duration, using contemporary planning, verification and delivery techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This single-arm, multicentre, phase-II study will test the shortened hypofractionated accelerated palliative RT regimen of 30\u2009Gy in 6 alternate-day fractions, with strict normal tissue dose constraints. We aim to recruit 37 patients across 4 sites within the West Midlands. Quality assurance for the RT is supported by the Radiotherapy Trials Quality Assurance Group (RTTQA). Patients with locally advanced or metastatic NSCLC, who are candidates for high-dose palliative RT, before or after first-line systemic therapy, are eligible for recruitment. The primary objective of this study is to assess the safety of the proposed dose-fractionation. Secondary objectives include evaluating toxicity profiles, patient-reported outcome measures, time to progression, feasibility and the National Health Service cost-saving.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      This study is conducted in accordance with the International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines and all applicable regulatory frameworks, including, but not limited to, the UK policy framework for health and social care research, as well as the Health Research Authority and Health and Care Research Wales regulations. Approval for the study was granted on 18 April 2024 (IRAS project ID: 332998; REC reference: 24\/WM\/0032). The chief investigator is responsible for obtaining informed consent from participants. Any individual delegated this responsibility is thoroughly authorised, trained and competent to conduct the informed consent process. On completion of the trial, the results will be shared with participants in a plain language summary and will be submitted for publication in a peer-reviewed journal. If successful, this study will inform a phase III randomised controlled trial to assess efficacy. For updates on the study, visit the study web page (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/research.mededcoventry.org\/About-Us\/Meet-The-Team\/TMU\/Ship-Rt\">https:\/\/research.mededcoventry.org\/About-Us\/Meet-The-Team\/TMU\/Ship-Rt<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06483308\">NCT06483308<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-111350","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:25:42Z","timestamp":1770049542000},"page":"e111350","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt): protocol for a single-arm, multicentre, phase II study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06483308","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-9377","authenticated-orcid":false,"given":"Raj Kumar","family":"Shrimali","sequence":"first","affiliation":[{"name":"Institute for Precision Diagnostic & Translational Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1118-9518","authenticated-orcid":false,"given":"Ellanna","family":"Griffin","sequence":"additional","affiliation":[{"name":"University of Warwick Medical School, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Sturgess","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Jones","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Hiller","sequence":"additional","affiliation":[{"name":"University of Warwick Warwick Clinical Trials Unit, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Rogers","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Hamilton","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Peebles","sequence":"additional","affiliation":[{"name":"Patient and Public Research Advisory Group, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bleddyn","family":"Jones","sequence":"additional","affiliation":[{"name":"Oxford Institute for Radiation Oncology, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Dunn","sequence":"additional","affiliation":[{"name":"University of Warwick Warwick Clinical Trials Unit, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026062610402600000_16.2.e111350.1","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA A Cancer J Clinicians"},{"key":"2026062610402600000_16.2.e111350.2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"2026062610402600000_16.2.e111350.3","unstructured":"Office for National Statistics . Cancer registration statistics, england: 2017. 2019."},{"key":"2026062610402600000_16.2.e111350.4","unstructured":"Cancer Research UK . Lung cancer statistics."},{"key":"2026062610402600000_16.2.e111350.5","unstructured":"NCRAS . National Cancer Registration & Analysis Service and Cancer Research UK: \u201cChemotherapy, Radiotherapy and Tumour Resections in England: 2013-2014\u201d Workbook. London, 2017."},{"key":"2026062610402600000_16.2.e111350.6","unstructured":"Royal College of Physicians . National Lung Cancer Audit Annual Report 2017 (for the Audit Period 2016). London, 2018."},{"key":"2026062610402600000_16.2.e111350.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753"},{"key":"2026062610402600000_16.2.e111350.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"2026062610402600000_16.2.e111350.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"2026062610402600000_16.2.e111350.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"2026062610402600000_16.2.e111350.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2026062610402600000_16.2.e111350.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026062610402600000_16.2.e111350.13","unstructured":"National Institute for Health and Care Excellence . Lung cancer: diagnosis and management. nice guideline [NG122]. 2019."},{"key":"2026062610402600000_16.2.e111350.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7010.899"},{"key":"2026062610402600000_16.2.e111350.15","unstructured":"The Royal College of Radiologists . Radiotherapy for Lung Cancer - RCR Consensus Statements. London, 2020."},{"key":"2026062610402600000_16.2.e111350.16","unstructured":"The Royal College of Radiologists . Radiotherapy dose fractionation, vol. BFCO(19)3. In: Radiotherapy Dose Fractionation. 2019: 49\u201357."},{"key":"2026062610402600000_16.2.e111350.17","article-title":"Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer","volume":"1","author":"Stevens","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062610402600000_16.2.e111350.18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0936-6555(96)80041-0","article-title":"Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status","volume":"8","author":"Macbeth","year":"1996","journal-title":"Clin Oncol"},{"key":"2026062610402600000_16.2.e111350.19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0936-6555(96)80042-2","article-title":"Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party","volume":"8","author":"Macbeth","year":"1996","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026062610402600000_16.2.e111350.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.03.023"},{"key":"2026062610402600000_16.2.e111350.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2020.05.003"},{"key":"2026062610402600000_16.2.e111350.22","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180111","article-title":"Modelling the influence of treatment time on the biological effectiveness of single radiosurgery treatments: derivation of \u201cprotective\u201d dose modification factors","volume":"92","author":"Jones","year":"2019","journal-title":"Br J Radiol"},{"key":"2026062610402600000_16.2.e111350.23","doi-asserted-by":"publisher","DOI":"10.1053\/clon.2001.9221"},{"key":"2026062610402600000_16.2.e111350.24","article-title":"The evolution of practical radiobiological modelling","volume":"92","author":"Jones","year":"2019","journal-title":"Br J Radiol"},{"key":"2026062610402600000_16.2.e111350.25","doi-asserted-by":"crossref","first-page":"102559","DOI":"10.1016\/j.ejmp.2023.102559","article-title":"Feasibility and safety of shortened hypofractionated high-dose palliative lung radiotherapy - A retrospective planning study","volume":"108","author":"Jones","year":"2023","journal-title":"Phys Med"},{"key":"2026062610402600000_16.2.e111350.26","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2026062610402600000_16.2.e111350.27","unstructured":"Shorter radiotherapy treatments could improve quality of life for patients with advanced lung cancer. Available: https:\/\/www.uhcw.nhs.uk\/news\/shorter-radiotherapy-treatments-could-improve-quality-of-life-for-patients-with-advanced-lung-cancer\/ [Accessed 30 Dec 2025]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-111350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:41:00Z","timestamp":1782495660000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-111350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-111350"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-111350","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}